The Nova Oculus III is a novel medical device, like goggles, worn over the eyes that administers a highly proprietary regimen of microcurrent to successfully treat dry macular degeneration without drugs, is non-invasive, proven completely safe and without pain.

The human body is essentially a system of fluids and electrical circuits. One of the main reasons the body fails is oxidation (rust) that interferes with the body’s functions, causing cell death. Macular degeneration, in particular, can be caused by a variety of factors causing this oxidation to occur – smoking, high cholesterol, excess weight, lack of exercise, diet, heredity, and disease. The Nova Oculus III introduces a low voltage microcurrent into the macula to stimulate cell health, act as an antioxidant, promote blood flow, and preserve (and even restore) vision. Microcurrent therapy is painless, safe, and very effective – particularly when combined with other good health practices to reduce oxidation and macular retinal health.

Anyone who is experiencing dry AMD can benefit from this treatment.

Yes, our clinical trial and years of additional clinical research, and one regulatory agency, Health Canada, have confirmed the complete safety of our microcurrent medical therapy to treat dry AMD.

Because our treatment is microcurrent based and is the only known effective treatment of its kind that can successfully slow the progression of dry AMD and restore vision for most users.

No. We are committed to offering treatment at a reasonable cost.

This can only be provided by your doctor.

No. This therapy is so new to the insurance industry that they have not had time to evaluate it for reimbursement.
However, Canada recently passed a new law, BILL C-284, An Act to Establish a National Strategy for Eye Care, which has a key focused on AMD and establishing health insurance reimbursement for our therapeutic treatment.

Our clinical trial and ongoing research program shows that patients using our therapy can experience lesser and slower AMD disease progression, with most experiencing a significant improvement in visual performance. Those who have been in the research program for years, using the device as prescribed, continue to maintain improved vision, especially when our therapy is combined with other mitigating behaviors such as stopping smoking, weight control, regular exercise, macular nutritional supplements, sun protection, etc.

Yes, our clinical trials and ongoing research show significant vision improvement for most Nova Oculus device users.

Microcurrent (low voltage) therapy has been used in medicine for over 100 years to treat many parts of the body – the brain, joints, muscles, and other areas. It is similar to the over-the-counter Transcutaneous Electrical Nerve Stimulation (TENS) units that many people use for pain management but scientifically developed for macular health. Microcurrent therapy is proven to be safe, effective, painless, easy to use, and inexpensive.

You are eligible for treatment with our medical therapy if you have been diagnosed with dry AMD and obtained a doctor’s prescription.

Presently we are seeking regulatory approval to treat all stages of dry AMD.

Yes, our clinical data has proven it can for most patients. Please refer to the information and testimonials on our website: www.NovaOculusMedical.com.

No. Our medical therapy has been demonstrated to show efficacy at all ages.

There are no pre-treatment or post-treatment requirements. For optimum treatment effect, patients should sit quietly in a reclined bed or chair during treatment.

The length of a session is 32 minutes.

For many, some vision improvement can be immediate; and generally, all patients have seen improvement within 3-4 treatments.

This up to the individual patient’s progress and their doctor to determine, but optimal results can take up to several months.

Yes. The Nova Oculus III can only be used with a doctor’s prescription and follow-up care.

This is a stand-alone medical therapy, which doctors generally recommend additional practices such as quitting smoking, exercise, diet, and macular nutritional supplements.

Yes, Nova’s technology is not a cure. Patient vision improvements are temporary. Our therapy is ongoing. Once the user has achieved their optimal restored vision, continued treatments will be prescribed by the user’s doctor to maintain best vision results.

Presently the Nova Oculus III is not available. It has undergone significant upgrades in the past year. We anticipate that it will receive regulatory approval for the new modifications for the Canadian market in the 2nd or 3rd quarter of 2025.

No. However, in addition to Canada we anticipate entry into Australia and Japan in 2025. These markets were not selected arbitrarily, but due to regulatory advantages presently unavailable in other countries.

Nova first acquired it from its inventor. The device has been greatly improved by our advisory board medical experts, scientists and engineers for greater efficacy of the treatment as well as in safety and comfort that our device now delivers.

No. “A painless, comfortable, portable device without any known side effects or drawbacks. Its ability to alter the course of millions of Canadians can’t be understated.”
-Kevin Parkinson MD, FRCSC | Principal Investigator for the Nova Oculus Device Clinical Trial

The primary source for up-to-date detailed information is subscription to Nova Community mailing list, with regular information releases. Please also follow us on social media.

Once the device is available in your country you may contact our in-country representative distributor to locate an authorized doctor.

For more information, please contact our team at info@novaoculus.com.